Related Experiment Video

Updated: Jun 12, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

New oral anticoagulant drugs in cardiovascular disease

Ingo Ahrens1, Gregory Y H Lip, Karlheinz Peter

  • 1Innere Medizin III, Kardiologie und Angiologie, Universitätsklinik, Hugstetter Strasse 55, Freiburg, Germany. ingo.ahrens@uniklinik-freiburg.de

Thrombosis and Haemostasis
|June 12, 2010
PubMed

Insights

Novel oral anticoagulants offer an alternative to traditional vitamin K antagonists (VKAs) for preventing thromboembolism. These new drugs, targeting factor Xa or thrombin, aim to improve predictability and reduce monitoring needs in cardiovascular disease management.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hematology

Background:

  • Oral anticoagulation has relied on vitamin K antagonists (VKAs) for over 60 years.
  • VKAs require continuous monitoring due to unpredictable pharmacodynamics and variable patient response.
  • Shortcomings of VKAs necessitate the development of alternative oral anticoagulants.

Purpose of the Study:

  • To review the clinical evaluation and pharmacological properties of novel oral anticoagulants (NOACs).
  • To critically analyze NOACs in late and earlier stages of clinical development.
  • To provide an outlook on the future of oral anticoagulation in cardiovascular disease.

Main Methods:

  • Review of clinical trials and pharmacological data for NOACs.
  • Focus on direct thrombin inhibitors and direct factor Xa inhibitors.
  • Analysis of NOACs in the context of cardiovascular disease, including atrial fibrillation and acute coronary syndromes.

Main Results:

  • Novel oral anticoagulants targeting factor Xa or thrombin (factor IIa) are now in clinical practice.
  • Dabigatran etexilate (direct thrombin inhibitor) and rivaroxaban (direct factor Xa inhibitor) have been approved.
  • Ongoing trials investigate these and other NOACs for various cardiovascular conditions.

Conclusions:

  • NOACs represent a significant advancement over VKAs, potentially offering improved predictability and reduced monitoring.
  • These agents are increasingly integrated into the management of thromboembolic disorders in cardiovascular disease.
  • The future of oral anticoagulation in cardiovascular disease is likely to involve a greater role for NOACs.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...